Background: Arteriovenous grafts made of polyurethane (PU) have the advantage of early cannulation obviating the placement of a central vein catheter in patients with an acute need for long-term hemodialysis. The aim of the present study was to evaluate the safety, efficacy and complication rate of PU vascular grafts for dialysis access in patients in whom early cannulation was performed.
Autogenous arteriovenous (AV) access thrombosis is one of the major complications that may occur some time after the creation of an AV fistula. Removal of thrombus plus the correction of the underlying stenosis will provide a functional AV access immediately, but the technical success and the long-term patency of this approach is unpredictable. Most patients ultimately require the creation of a new AV fistula or, in the absence of an autogenous option, the placement of a prosthetic graft. Because a new AV access will need a 2-to 8-week maturation period until it can be cannulated, a central venous catheter (CVC) will also need to be placed. To avoid the inconvenience, the perioperative complications and the long-term risks of CVCs, several early cannulation vascular grafts have been manufactured that can either eliminate the need or at least minimize the duration of CVC use. A recent meta-analysis, published in 2015, showed that early cannulation of Flixene (Atrium, Hudson, NH), Avflo (Nicast Ltd, Lod, Israel), Rapidax (Vascutek, a Terumo Company, Inchinnan, United Kingdom), and Accuseal (W. L. Gore, Flagstaff, Ariz) grafts is possible, but could not reach any conclusion about Vectra (Thoratec Corporation, CR Bard, Inc, Pleasanton, Calif), because "there was no evidence of the use of Vectra within 2 weeks of placement." 1 The aim of the present study was to evaluate the safety, efficacy, and complication rate of the polyurethane (PU) vascular graft for dialysis access in patients in whom early cannulation was performed.
METHODS
Between January 2007 and December 2015, 422 patients with an AV access thrombosis were admitted to our department. Of these patients, 114 were treated with the creation of a new, autogenous AV fistula, 132 with a new AV graft (125 in a straight arm configuration and 7 as a loop in the forearm), 121 with graft thrombectomy, and 55 with the insertion of a CVC only. The choice of type of intervention was based on clinical examination plus color duplex ultrasonography examination looking for suitable veins for either native fistula creation or graft implantation. CVCs as a permanent access were only used in patients with exhausted access sites in both upper limbs. The current study is focused on the 125 patients who were treated with the implantation of a straight AV graft in the arm between the brachial artery and the axillary vein. In 64 (51.2%) of them, a PU vascular access graft (Vectra) was used and in the rest 61 (48.8%) patients an expanded polytetrafluoroethylene (PTFE) graft (Maxiflo, Vascutek, a Terumo Company, Inchinnan, United Kingdom) plus a CVC. The selection of graft type was an individual surgeon's decision. Factors that were taken into account were the presence of an already placed CVC for urgent hemodialysis, the patency of the internal jugular veins, and patient preference based on their preconception about the performance of early cannulation grafts.
At the time of admission, a complete medical history was taken and the following factors and comorbidities were recorded: age, sex, hypertension (blood pressure >140 mmHg systolic or 90 mm Hg diastolic, or both), coronary artery disease (angina pectoris, myocardial infarction, coronary artery bypass grafting procedure, or coronary percutaneous transluminal angioplasty) and diabetes mellitus (controlled by diet, oral hypoglycemic agents, or insulin, or with fasting glucose levels > 7 mmol/L).
All patients received 1 g vancomycin intravenous 30 minutes before the operation as prophylaxis. Prolene 5/0 suture was used for the anastomoses. All operations were performed by the same operators under local anesthesia and using the same surgical technique. Before implantation, the PU grafts were soaked in a sterile solution of normal physiologic saline. A sheath tunneler was placed subcutaneously through which the grafts were pushed rather than pulled. According to the manufacturer's instructions, owing to the compliant nature of the PU graft, it will expand approximately 0.5 cm once exposed to normal arterial pressure. Therefore, the grafts were trimmed to a length approximately 0.5 cm shorter than the length measured. The ends of the grafts were beveled to accommodate a smooth lie of the graft on both the axillary vein and the brachial artery.
Access patency was confirmed perioperatively either by palpation or Doppler examination. No intraoperative anticoagulation protocol was applied. Patients who were receiving antiplatelet or anticoagulant drugs continued their therapy. Written informed consent was obtained from all study participants and the study was approved by the ethical committee of the hospital. PU grafts were generally cannulated 24 hours after placement. Shorter intervals from placement to cannulation were required when immediate dialysis was necessary and longer intervals when excessive edema prevented the palpation of the graft. PTFE grafts were generally cannulated after a minimum maturation period of 3 weeks and not until the associated edema had resolved.
Standard cannulation technique, as recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Vascular Access was used. 2 In brief, blood access needles were inserted at a 45 angle with the bevel up until the graft was penetrated. The rope ladder technique (rotation of the cannulation sites) was used with strict adherence to aseptic principles.
Follow-up. Grafts were monitored using dynamic dialysis venous pressure measurements weekly and by static venous pressure measurements every 2 weeks, as recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Vascular Access. 2 Measurements were performed by experienced nephrologists in each dialysis center. Primary, primary assisted, and secondary graft patency was defined according to the reporting standards for AV accesses of the Society for Vascular Surgery and the American Association for Vascular Surgery. 3 Complications, including graft infection, pseudoaneurysm, seroma, hand ischemia, and graft occlusion, were diagnosed by clinical examination and verified by color duplex ultrasonography examination. Graft infection was treated by removal of the infected graft material combined with antibiotic therapy. 2 Pseudoaneurysms that exceeded twice the diameter of the graft or those that were increasing in size were treated by resection and segment interposition. Stenosis of the venous anastomosis was treated by stenting, and graft thrombosis was treated by thrombectomy plus correction of the underlying cause, which is usually stenosis of the venous anastomosis. Medical files kept in our hospital as well as in each dialysis center were reviewed by J.D.K., G.M., E.A., and K.K., and all of the recorded complications were entered in the statistical analysis.
Statistical analysis. Quantitative variables were expressed as means and compared with the Student t test. Qualitative variables were expressed as proportions and compared with the c 2 test. Patency rates were calculated using Kaplan-Meier analysis and compared between the two groups with the log-rank test. Cox proportional hazards analysis was conducted to determine whether graft patency was affected by other patient characteristics (age, sex, comorbidities). Statistical analysis was performed with the use of the SPSS 19 software (IBM Corp, Somers, NY). Results were considered statistically significant at P < .05. 
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RESULTS
Patient characteristics did not differ significantly between the two groups (Table) . All of the grafts were 6 mm in diameter. PU grafts were cannulated within 2 hours (day 0) to 5 days (median, 1 day), whereas PTFE grafts were cannulated after 3-5 weeks (median, 28 days). Median follow-up time was 27 months (range, 0-71 months). None of the patients was lost to follow-up.
None of the CVCs, which were used for hemodialysis until the grafts could be cannulated, was infected. Five patients in the PU group developed graft infection after 2-39 months, whereas in the PTFE group there were 3 graft infections after 4-33 months (Fig 1) . The cumulative infection rate at 5 years was 13% in the PU group vs 8% in the PTFE group. Statistical analysis revealed that there was no difference in the graft infection rate between the two groups (P ¼ .6). The graft that was infected within the first 3 months after implantation was treated by total graft excision, and the remaining 7 infected grafts were treated by partial graft excision of the involved graft segment and the implantation of a new graft with a new tunnel. One of the patients in the PU group who was treated by partial graft excision developed recurrent graft infection in the remaining segment, necessitating total graft removal. Staphylococcus aureus was the responsible bacterium, isolated from all graft cultures.
None of the patients in the PU group developed a pseudoaneurysm necessitating intervention, compared with one patient in the PTFE group who developed a pseudoaneurysm at a needle-stick site with skin changes requiring replacement of the involved graft segment with a new PTFE graft. None of the patients in either group developed access-related hand ischemia, edema persisting after the perioperative period, or seroma.
Primary patency in the PU group was 73%, 48%, 42%, 36%, and 26% at 1, 2, 3, 4, and 5 years, respectively (Fig 2) . The Kaplan-Meier cumulative median patency was 23 months. Primary patency in the PTFE group was 74%, 53%, 39%, 31%, and 27% at 1, 2, 3, 4, and 5 years, respectively. The Kaplan-Meier cumulative median patency was 26 months. Statistical analysis revealed that primary patency did not differ significantly between the two groups (P ¼ .7).
During follow-up, there were only five patients (2 in the PU group and 3 in the PTFE group) that were found to have increased dynamic or static venous pressures and subsequently underwent percutaneous transluminal angioplasty with bare metal stent placement at the venous anastomosis. No difference was found in the primary assisted patency rate between the PU and the PTFE group (P ¼ .7). Secondary patency in the PU group was 84%, 57%, 50%, 41%, and 28% at 1, 2, 3, 4, and 5 years, and the respective values in the PTFE group were 90%, 66%, 43%, 34%, and 27% (Fig 3) . Statistical analysis verified that secondary patency did not differ significantly between the two groups (P ¼ .984) The Kaplan-Meier cumulative median secondary patency was 42 months in the PU group vs 33 months in the PTFE group. Among the patient demographics and comorbidities, the only factor that was found to affect graft patency was diabetes mellitus. Median primary patency in diabetics receiving a PU graft was 18 months vs 49 months in nondiabetics (P < .005; Fig 4) . The respective values in patients with PTFE grafts were 15 vs 36 months (P < .05; Fig 5) .
During follow-up, 17 patients died (8 patients in the PU group and 9 in the PTFE group) of causes unrelated to the grafts. The causes of death were myocardial infarction in 8 patients, congestive heart failure in 3, cancer and stroke in 2 patients each, and lung infection and pulmonary embolism in 1 patient each. No difference was found in the mortality rate between the PU and the PTFE group (P ¼ .7).
DISCUSSION
Resistance to thrombosis, infection and degradation, immediate accessibility, and mechanical properties similar to native vessels to reduce intimal hyperplasia at the anastomotic sites represent some of the properties of the ideal vascular graft for hemodialysis access. With respect to immediate accessibility, this is the first study to report outcomes of PU vascular access grafts with a median cannulation time of only 1 day. This is particularly important if CVCs are to be avoided, taking full advantage of the PU vascular access graft.
There are concerns, however, that early cannulation may come at an increased risk of infection. Peng et al 5 have reported an infection rate of 30% with a median follow-up period of only 12 months. Early cannulation cannot be held responsible for this increased risk of infection, because the median period from implantation to cannulation was 19 days. The inclusion of grafts placed in the thigh may have played a role in this increased risk of infection, although the percentage of such grafts was only 10%. Maya et al 6 have also reported high rates of infection, with the cumulative risk of infection at 1 year being 23% for PU upper extremity grafts and 37.5% for PU thigh grafts. These rates were significantly higher than the respective rates of 5% and 21% of PTFE grafts. PU grafts were routinely cannulated 24-48 hours after their implantation, whereas PTFE grafts were cannulated after 2-3 weeks. Similarly, Allen et al 7 have found a 19% rate of infection in a group of patients receiving PU grafts that were cannulated after a median period of 3 days and were followed for a median of 10 months. Among these grafts, 11% were placed in the thigh. In contrast, there are several papers, like ours, reporting low rates of infection that are comparable with the infection rates of PTFE grafts. Kakkos et al 8 have found an 11% infection rate at 3 years after the implantation of a PU graft that was similar to the 8% infection rate of Carboflo grafts. Only 2.5% of the PU grafts were placed in the thigh, whereas the respective proportion of Carboflo grafts was 0.8%. In the series of Kiyama et al, 9 the infection rate of PU grafts, 23% of which were placed in the thigh, was 13.3%. The mean interval to cannulation was 10.8 days and the mean follow-up period 21 months. Interestingly, in a study focused on human immunodeficiency virus-positive patients with end-stage renal disease, the infection rate of PU grafts was only 10%, which was attributed by Schild et al 10 to the selfsealing property of the PU graft minimizing the development of perigraft hematoma. It is also interesting that the lowest rate of infection reported so far was found in a randomized control trial of PU vs expanded PTFE grafts and was equal for both groups (5.6%). The mean time to first use was significantly shorter for PU grafts (19.8 6 33.0 days) compared with grafts of control patients (41.2 6 47.8 days), but was still quite long. 11 Our findings confirm that PU grafts are as good as expanded PTFE grafts in terms of infection risk. This finding is important because it comes from a study with the shortest interval from implantation to cannulation and the longest follow-up. The 13% infection rate was calculated by Kaplan-Meier analysis and represents the cumulative infection rate at 5 years of follow-up.
Most of the studies agree that the PU graft is associated with a low risk of pseudoaneurysm formation, which is attributed to the self-sealing properties of the PU and the resistance to degradation of the three-layered cast graft. Pseudoaneurysm formation rate was zero in our study as well as in the studies of Kiyama et al 9 and Glickman et al, 11 1% in the study of Allen et al, 7 and 3.5% in the study of Peng et al. 5 Kakkos et al 8 have reported the highest rate of pseudoaneurysm formation (17%), which did not differ from the 23% pseudoaneurysm formation rate of PTFE grafts. Patency rates of PU grafts at 1 year show a remarkable variance, with primary patency ranging from 28% to 73% and secondary patency from 42% to 86%. [5] [6] [7] [8] [9] [10] [11] At 3 years, the reported primary patency ranges from 15% to 52%, with secondary patency of about 70%. 5, 8 These differences could be attributed to the different selection criteria for the placement of a PU graft, the various sites where the grafts were placed (forearm, upper arm, thigh), the different configurations (straight, loop) or the different graft size (5 or 6 mm). Our study is focused on straight, upper arm, 6-mm PU grafts that were placed for an acute need of hemodialysis in patients with a previous AV access thrombosis. Our primary and secondary patency rates at 1 year compare well with those reported in the literature, but we were unable to reproduce the reported 70% secondary patency rates at 3 years. Our good patency rates at 1 year are probably owing to the fact that all of the grafts included in the present study were placed in patients with a previous AV access thrombosis, so the vessels in the ipsilateral limb were already mature. Moreover, all of the grafts were placed in the upper arm, where patency rates are known to be better than those achieved in the forearm, owing to the larger size of the vessels. 8 The nonrandomized design should be acknowledged as the main limitation of our study. Although the two patient groups were similar in all of the clinical characteristics that were compared in the Table, unintentional and not measurable bias introduced at the time of graft type selection cannot be excluded.
Another point of criticism may be the relatively long interval between implantation and cannulation of the PTFE grafts (range, 3-5 weeks; median, 28 days), if we take into account that the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommend a maturation period of as short as 2 weeks. This is, however, a real-life study reflecting the everyday clinical practice of nephrologists in various dialysis units. In this context, our median time of 28 days from access surgery to first cannulation is similar to the 34 days reported by Lee et al 12 and much lower than the 70 days reported by Leake et al 13 in a recent study of 6286 patients. 13 As mentioned, in the single randomized comparison of PU vs PTFE grafts, the mean time to first use was 19.8 days for the PU grafts vs 41.2 days for the PTFE grafts.
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In conclusion, The PU vascular access graft offers the advantage of early, even immediate cannulation in patients with an acute need for hemodialysis. Infection, pseudoaneurysm formation, primary and secondary patency rates were satisfactory and comparable with those offered by the commonly used PTFE grafts. 
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